Friday, February 24, 2023

Exclusive Report: Manufacturers Identify the Three Critical Drivers of Hub Success

Today’s guest post comes from Matt Hall, President of Patient Solutions at CareMetx.

Matt shares three key findings from CareMetx’s exclusive new survey on patient support services for specialty pharmaceuticals. To learn more, download CareMetx’s free 2022 Report - Patient Services Trends

Read on for Matt’s insights.

Exclusive Report: Manufacturers Identify the Three Critical Drivers of Hub Success
By Matt Hall, President, Patient Solutions, CareMetx

With chronic and rare diseases growing more prevalent, it’s no surprise the market for specialty pharmaceuticals is on the rise.

In 2022, the global pharmaceutical market value was estimated at $1.48 trillion U.S. dollars, and is expected to grow at a compound annual growth rate of 11.3% through 2028. As manufacturers try to keep pace, the ability to meet patient needs throughout the therapy journey doesn’t come without challenges. These challenges place greater demands on both manufacturers and the hub providers they partner with to help support their patient service programs.

CareMetx recently took a deep dive into this topic, surveying more than 100 people from leading pharmaceutical organizations across the globe, along with a sample of healthcare providers and industry consultants. Our participants spanned a spectrum of roles that influence patient services, including medical, commercial, sales, marketing, research and development, market access, procurement, and senior leadership.

Our goal was to uncover how various patient services are changing the way healthcare stakeholders do business, and to learn what manufacturers and hub providers can do to keep up. The results, captured in 2022 Report - Patient Services Trends, reveal a key theme: the growing need for more patient-centric solutions. It seems centering the patient is what truly allows manufacturers to deliver greater value. Below, I provide more detail about our key findings.

What Did Survey Participants Say They Prioritize Most?

Most survey participants shared that their greatest priorities revolve around therapy initiation, adherence, and patient satisfaction. However, by gathering insight from leaders in a diverse group of roles, the results revealed how various stakeholders within an organization may differ in the priorities that influence their personal views on patient services solutions.

For instance, among individuals directly involved in bringing new therapies to market—such as research and development or commercial teams—there was a strong desire to improve patient adoption of new and efficacious drugs. Alternatively, medical teams surveyed placed the greatest importance adherence- ensuring patients adhere to the prescribed treatment plan and optimize the therapy dosage.

Three Key Value Drivers Emerged. What Were They?

When manufacturers invest in a hub solution to support the launch of a new specialty drug or medical device, they expect that hub to provide strong value. To better understand how manufacturers define value in the context of an effective patient services program, the survey drilled down into the specific factors that drive the hub decision. What emerged from the responses are three key drivers of value for patient services solutions.
  1. A Holistic View of Therapy Initiation

  2. For one, it’s common for patient services solutions to address the portions of the patient journey that reduce cost-related obstacles to initiation. For instance, most programs handle benefit verification and facilitate financial assistance programs like co-pay cards. But paving the way for successful initiation goes far beyond reducing cost as an impediment.

    As the results revealed, the most valuable patient services solutions instead approach therapy initiation more holistically, recognizing the many other challenges that can stand in the way of patients getting off to a positive start on treatment. Manufacturers want hub providers that take a more comprehensive approach to supporting patient initiation, addressing the multitude of obstacles that often keep patients from starting a specialty therapy successfully—from difficulties using self-injected drugs to a lack of transportation to get to an infusion site, for example.

  3. An Integrated Solution

  4. Second, manufacturers and healthcare providers both seemed to recognize that patients find the healthcare system difficult and confusing to navigate, time-consuming and inefficient to work within, and frustrating to deal with.

    As a result, responses revealed they seek patient services solutions that use an integrated approach to minimize those administrative pain points. For example, hubs that can provide a seamless experience for patients and physicians by integrating the various, often disparate systems and data sources involved will go a long way toward improving the patient journey.

  5. Data that Supports Insights

  6. Finally, an outsourced patient services program can generate great stores of data about critical points along the patient journey. However, that data provides little value unless it enables manufacturers to glean meaningful insights that they can leverage to improve their therapy programs. The results show manufacturers see great value in gaining clearer visibility into how their drug programs are performing against the most relevant metrics, and the ability to use that data to drive insights that inform future investment decisions.
The CareMetx 2022 Report - Patient Services Trends offers a comprehensive window into how specialty pharmaceutical patient services are evolving. Review more in-depth results of the topics above and discover where manufacturers see their priorities over the next 18 months, what they want and need in a patient services hub provider, and how today’s vendors are positioned to meet their needs and align with their business objectives. The report also outlines five proven best practices that can assist manufacturers in gaining optimal value from their patient services programs. Click here to download the free CareMetx report.

Sponsored guest posts are bylined articles that are screened by Drug Channels to ensure a topical relevance to our exclusive audience. These posts do not necessarily reflect our opinions and should not be considered endorsements. To find out how you can publish a guest post on Drug Channels, please contact Paula Fein (

No comments:

Post a Comment